Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Poor quality product administered, Product temperature excursion issue
Clinical narrative: Patient was administered with vaccine that experienced more than 1 temperature excursion during 33 weeks on 2021; Patient was administered with vaccine that experienced more than 1 temperature excursion during 33 weeks on 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Patient was administered with vaccine that experienced more than 1 temperature excursion during 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Patient was administered with vaccine that experienced more than 1 temperature excursion during 33 weeks on 2021) in a 25-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 031L20A and 003B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 14-Feb-2021 at 2:53 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 21-Mar-2021 at 10:04 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to .5 milliliter. In 2021, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Patient was administered with vaccine that experienced more than 1 temperature excursion during 33 weeks on 2021). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Patient was administered with vaccine that experienced more than 1 temperature excursion during 33 weeks on 2021). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Patient was administered with vaccine that experienced more than 1 temperature excursion during 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Patient was administered with vaccine that experienced more than 1 temperature excursion during 33 weeks on 2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Age of patient was reported as 25.67 and 25.77 for dose 1 and 2 respectively.  Concomitant products were not provided.  On 09-Feb-2021, vaccines with batch number 031L20A were moved to the fridge. On 12-Feb-2021, three vials were moved to clinic. On the same day at 09 AM, vials underwent temperature excursion with temperature 29 degrees Fahrenheit (F) and between 10 AM to 11 AM vials underwent temperature excursion with temperature 35 F. On 13-Feb-2021, 30 vials were moved to clinic. On the same day at 09 AM, vials underwent temperature excursion with temperature 32 F. On 14-Feb-2021, 20 vials were moved to clinic. On the same day between 09 AM to 11 AM, vials underwent temperature excursion with temperature 32 F and at 2 PM, with temperature 35 F. The vaccine beyond use date (BUD) was reported as 10-Mar-2021. On 16-Mar-2021, vaccines with batch number 003B21A were moved to the fridge. On 21-Mar-2021, 10 vials were moved to clinic. On the same day between 09 AM to 11 AM, vials underwent temperature excursion with temperature in range of 32 to 34 F. The vaccine BUD was reported as 15-Apr-2021.  The condition of vaccine prior to vaccination was not frozen. It was reported that, the storage condition at the time of the excursion was cooler storage during high-pace COVID-19 vaccination clinic.  The vials were only punctured right before administration and all doses were drawn from the vial due to high-pace clinic.  Temperature recordings were taken using a traceable temperature monitor at every hour.  It was reported that, the patient was administered with vaccine that experienced more than 1 temperature excursion during 33 weeks on 2021. The health care professional explained that each time a vial was put into a cooler, there was a period of 1 hour or 1 hour and a half approximately, when the temperature data logger registered 34- or 35-F.  Treatment medications were not reported.   This case was linked to MOD-2022-566976 (Patient Link).